4.7 Article

Dose-response Effect of Incarceration Events on Nonadherence to HIV Antiretroviral Therapy Among Injection Drug Users

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 203, Issue 9, Pages 1215-1221

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jir032

Keywords

-

Funding

  1. Abbott Laboratories
  2. Agouron Pharmaceuticals
  3. Boehringer Ingelheim Pharmaceuticals
  4. Borean Pharma AS
  5. Bristol-Myers Squibb
  6. DuPont Pharma
  7. Gilead Sciences
  8. GlaxoSmithKline
  9. Hoffmann-La Roche
  10. Immune Response Corporation
  11. Incyte
  12. Janssen-Ortho
  13. Kucera Pharmaceutical
  14. Merck Frosst Laboratories
  15. Pfizer Canada
  16. Sanofi Pasteur
  17. Shire Biochem
  18. Tibotec Pharmaceuticals
  19. Trimeris
  20. National Institutes of Health [R01DA021525]
  21. Canadian Institutes of Health Research [MOP-79297, RAA-79918]
  22. Michael Smith Foundation for Health Research
  23. Canadian Institutes of Health Research (CIHR)

Ask authors/readers for more resources

Background. Although some studies have identified impressive clinical gains for incarcerated HIV-seropositive injection drug users (IDUs) undergoing antiretroviral therapy (ART), the effect of incarceration on adherence to ART remains undetermined. Methods. We used data from a long-term community-recruited cohort of HIV-seropositive IDUs, including comprehensive ART dispensation records, in a setting where HIV care is free. We estimated the relationship between the cumulative burden of incarceration, measured longitudinally, and the odds of < 95% adherence to ART, with use of multivariate modeling. Results. From 1996 through 2008, 490 IDUs were recruited and contributed 2220 person-years of follow-up; 271 participants (55.3%) experienced an incarceration episode, with the number of incarcerations totaling 1156. In a multivariate model, incarceration had a strong dose-dependent effect on the likelihood of nonadherence to ART: 1-2 incarceration events (adjusted odds ratio [AOR], 1.49; 95% confidence interval [95% CI], 1.03-2.05), 3-5 events (AOR, 2.48; 95% CI, 1.62-3.65), and > 5 events (AOR, 3.11; 95% CI, 1.86-4.95). Conclusions. Among HIV-seropositive IDUs receiving ART, an increasing burden of incarceration was associated with poorer adherence in a dose-dependent fashion. Our findings support improved adherence support for HIV-seropositive IDUs experiencing incarceration.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available